Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German testicular cancer study group
Schmoll, HJ × Kollmannsberger, C Metzner, B Hartmann, JT Schleucher, N Schöffski, Patrick Schleicher, J Rick, O Beyer, J Hossfeld, D Kanz, L Berdel, WE Andreesen, R Bokemeyer, C #
Grune & Stratton
Journal of Clinical Oncology vol:21 issue:22 pages:4083-4091
Purpose : Patients with disseminated germ cell cancer and poor prognosis (international Germ Cell Cancer Collaborative Group [IGCCCG] classification) achieve only a 45% to 50% long-term survival by standard chemotherapy. First-line high-dose chemotherapy might be able to improve the result. This analysis reports toxicity and long-term results of a large phase I/II study of sequential high-dose etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced germ cell tumors.